Lacktman Comments on Barriers to Using Telemedicine to Treat Opioid Addiction
26 October 2017
Partner Nate Lacktman is quoted in a Politico Pro article, “Trump’s call to bolster virtual opioid treatment lacks muscle, critics say,” about ways in which the Trump administration could facilitate the use of telemedicine to treat opioid addiction.
Lacktman said it may be possible for the president to instruct the Drug Enforcement Administration to waive parts of a 2008 law that bars doctors from prescribing anti-addiction medications to patients they haven’t first seen in person. “We really need to see more from the White House on an actual rule or executive order to see what this would look like,” he said.
Lacktman said it may be possible for the president to instruct the Drug Enforcement Administration to waive parts of a 2008 law that bars doctors from prescribing anti-addiction medications to patients they haven’t first seen in person. “We really need to see more from the White House on an actual rule or executive order to see what this would look like,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”